Biomed-101

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameBiomed-101
Drug Alias NameBiomed-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeukotriene B4 receptor antagonists
TargetsLeukotriene B4 receptor
Therapy Area/IndicationsExtravasation of Diagnostic and Therapeutic MaterialsKidney Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiomedicines
Active IndicationsN/A
Inactive IndicationsExtravasation of Diagnostic and Therapeutic MaterialsKidney Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A